Topics

Latest "Sanofi Pharmaceuticals Incorporated" News Stories

04:53 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "Sanofi Pharmaceuticals Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Sanofi Pharmaceuticals Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sanofi Pharmaceuticals Incorporated for you to read. Along with our medical data and news we also list Sanofi Pharmaceuticals Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sanofi Pharmaceuticals Incorporated Companies for you to search.

Showing "Sanofi Pharmaceuticals Incorporated" News Articles 1–25 of 6,300+

Relevant

Sanofi: EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said that the European Commission granted conditional marketing authorization for Libtayo or cemiplimab to treat adu...


Sanofi forks over $260M to end diabetes partnership

Sanofi will pay Lexicon Pharmaceuticals $260 million to terminate a partnership related to the development of a diabetes drug.

FDA expands indication for Regeneron, Sanofi's Praluent

Regeneron Pharmaceuticals and Sanofi's Praluent has been approved by the FDA for use to reduce the overall risk of major adve -More- 


FDA expands use of Regeneron, Sanofi's Dupixent

Regeneron Pharmaceuticals and Sanofi's Dupixent has been approved by the FDA for use in adult patients with uncontrolled chro -More- 

Novartis Pharma head to become new Sanofi CEO

French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with Paul Hudson, CEO at Novartis Pharmaceuticals. The decision was made on 6 June, when Sanofi’s Board of Directors voted unanimously to approve Brandicourt’s replacement. Hudson will take up the mantle on 1 September this year. Image caption:  ...

Regeneron-Alnylam-Sanofi RNAi partnerships: what does the future hold?

Alnylam Pharmaceuticals has announced a collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new RNA interference (RNAi) therapeutics for...Read More... The post Regeneron-Alnylam-Sanofi RNAi partnerships: what does the future hold? appeared first on Pharmaceutical Technology.

Sanofi to pay Lexicon $260m over terminated Zynquista alliance

Lexicon Pharmaceuticals has announced a $260m settlement with Sanofi over the termination of their alliance, which focused on the development...Read More... The post Sanofi to pay Lexicon $260m over terminated Zynquista alliance appeared first on Pharmaceutical Technology.

Sanofi ends partnership with Lexicon after release of Phase 3 data

French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes drug Zynquista (sotagliflozin). Sanofi terminated its partnership with Lexicon over the once daily, dual SGLT1 and SGLT2 inhibitor, used in combination with insulin for both Type 1 and Type 2 diabetes. Shares in Lexicon dropped by as much as 48% on announcement of...

Sanofi Terminates Partnership With Lexicon To Develop Diabetes Drug

PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) said that it terminated its partnership with Lexicon Pharmaceuticals Inc (LXRX) to develop, manufacture, and commercialize Zynquista in all ongoing global typ...

Sanofi to pay Lexicon $260 million for terminated partnership

Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Regeneron And Sanofi Say CHMP Adopts Positive Opinion For Dupixent

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended Dupixent be approved...

FDA approves expanded label for Regeneron/Sanofi's Dupixent

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

U.S. judge rules for Sanofi in Amgen patent fight

A U.S. judge on Wednesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which make a rival drug.

Sanofi Selects Novartis Executive to Replace Retiring CEO

Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.

Regeneron-Sanofi’s Praluent secures FDA approval for cardiac indications

Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) has received US Food and Drug Administration (FDA) approval. The drug is designed to mitigate the...Read More... The post Regeneron-Sanofi’s Praluent secures FDA approval for cardiac indications appeared first on Pharmaceutical Technology.

Regeneron-Sanofi’s Praluent secures FDA approval for cardiac illnesses

Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) has received US Food and Drug Administration (FDA) approval. The drug is designed to mitigate the...Read More... The post Regeneron-Sanofi’s Praluent secures FDA approval for cardiac illnesses appeared first on Pharmaceutical Technology.

Sanofi and Regeneron’s REGN3500 trial meets primary endpoint

Sanofi and Regeneron Pharmaceuticals’ Phase II trial of investigational IL-33 antibody REGN3500 (SAR440340) has met the primary endpoint of improvement...Read More... The post Sanofi and Regeneron’s REGN3500 trial meets primary endpoint appeared first on Drug Development Technology.

Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) after the type 1 and type 2 diabetes candidate showed mixed results in three Phase III trials, including disappointing outcomes among patients with chronic kidney disease (CKD). The post Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabet...

Sanofi und Regeneron erzielen Punktsieg in Patentstreit gegen Amgen

Von Maria Armental NEW YORK (Dow Jones)--Der französische Pharmakonzern Sanofi hat gemeinsam mit Regeneron Pharmaceuticals in einem langjährigen Patentstreit mit Amgen einen Sieg vor einem US-Geri...

Sanofi Reports Strong Second Quarter Driven by Dupixent Launch and Vaccine Sales

Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Sanofi Gains US OTC Rights For Tamiflu To Treat Influenza

SOUTH SAN FRANCISCO (dpa-AFX) - Sanofi has signed an agreement with Roche, under which, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketin...

Sanofi beendet Kooperation mit Lexicon bei Diabetes-Medikament

Von Dave Sebastian PARIS (Dow Jones)--Sanofi beendet die Kooperation mit dem US-Pharmaunternehmen Lexicon Pharmaceuticals beim Diabetes-Medikament Zynquista, teilte der französische Pharmakonzern ...

Regeneron, Sanofi: European Commission Approves New Indication For Dupixent

PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Commission has approved a new indication for Dupixent in chronic rhinosinusitis with nasal polyposis. Dup...

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which sells a rival drug.

Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi

THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM (sotagliflozin) and the settlement of its related disputes with Sanofi, each effective September 9, 2019. In connection with the termination, Lexicon will regain all ri


Quick Search

News Quicklinks